Nexalin Technology, Inc. (NXL): R&D Expense
$1.08M
Year ended 2025-12-31
$1.36M
Trailing 12 months to 2026-06-30
+28.5%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.08M | -9.0% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $1.19M | -38.0% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $1.92M | +276.1% | 2025-09-23, From 2023-01-01 |
| 2022-12-31 | $511.0K | +267.6% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $139.0K | n/a | 2023-03-27, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | 2025-12-31 | $1.08M | -9.0% |
| iTonic Holdings Ltd (ITOC) | 2025-12-31 | $459.1K | +392.0% |
| Guided Therapeutics Inc (GTHP) | 2025-12-31 | $469.0K | -10.8% |
| ADM Tronics Unlimited, Inc. (ADMT) | 2026-03-31 | $545.0K | +5.4% |
| Neuraxis, Inc (NRXS) | 2025-12-31 | $493.6K | +13.8% |
| Nuwellis, Inc. (NUWE) | 2025-12-31 | $2.71M | -15.5% |
| Escalon Medical Corp (ESMC) | 2025-06-30 | $753.1K | +9.4% |
| CapsoVision, Inc (CV) | 2025-12-31 | $18.31M | +21.1% |
| Hyperfine, Inc. (HYPR) | 2025-12-31 | $17.45M | -22.4% |
Compare NXL, ITOC, GTHP, ADMT side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗